- Stigma, Shame Hit Many Gay Men Affected by Mpox Outbreak
- Calories, Not Meal Timing, Key to Weight Loss: Study
- Dietary Changes May Beat Meds in Treating IBS
- Screen Pregnant Women for Syphilis, Ob-Gyn Group Advises
- Even With Weight Gain, Quitting Smoking in Pregnancy Still Best for Health
- A-Fib Is Strong Precursor to Heart Failure
- One Neurological Factor Keeps Black, Hispanic Patients From Alzheimer’s Clinical Trials
- Managing Blood Sugar After Stroke Could Be Key to Outcomes
- Dozens of COVID Virus Mutations Arose in Man With Longest Known Case
- Blood Test Might Someday Diagnose Early MS
Extended-Release Hydrocodone Painkiller Approved
FRIDAY, Oct. 25Zohydro ER (hydrocodone bitartrate extended-release) has been approved by the U.S. Food and Drug Administration for severe pain that requires round-the-clock long-term treatment, the agency said Friday in a news release.
Citing the potential for opioid abuse or dependency, even if the product is used as prescribed, the agency said the drug should be used only in cases when other painkillers have proven ineffective. The schedule II controlled substance should only be used to treat daily, chronic pain, not for as-needed pain relief, the FDA said.
The agency said it has ordered post-marketing studies of Zohydro ER to evaluate use beyond 12 weeks, and its overall potential for abuse.
The drug was evaluated in clinical studies involving more than 1,100 people with chronic pain. The most common side effects included constipation, nausea, drowsiness, headache, dizziness, dry mouth and itching.
Zohydro ER is produced by Zogenix, based in San Diego.
More information
To learn more about chronic pain, visit the U.S. National Institute of Neurological Disorders and Stroke.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.